Protagenic Therapeutics, Inc. (PTIX)
$0.372
+0.05 (+16.21%)
Rating:
Recommendation:
-
Symbol | PTIX |
---|---|
Price | $0.372 |
Beta | 0.200 |
Volume Avg. | 0.02M |
Market Cap | 6.430M |
Shares () | - |
52 Week Range | 0.3111-1.05 |
1y Target Est | - |
DCF Unlevered | PTIX DCF -> | |
---|---|---|
DCF Levered | PTIX LDCF -> | |
ROE | -44.83% | Strong Sell |
ROA | -46.58% | Strong Sell |
Operating Margin | - | |
Debt / Equity | 11.82% | Neutral |
P/E | -1.77 | Sell |
P/B | 0.87 | Buy |
Latest PTIX news
About
Download (Excel)Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.